NMPA and FDA approve initiation of Ph 2 trial (COMPASSION-36/AK104-225) of cadonilimab combo in previously treated HCC patients August 5, 2025
FDA Clears IND application for Ph 1/2 Trial of ABT-301 Triplet Therapy for Advanced CRC August 5, 2025
Imfinzi granted Priority Review and Breakthrough Therapy Designation in the US for patients with resectable early-stage gastric and GEJ cancers July 29, 2025
Positive Mid-year Safety and Efficacy Data from Ph 2 Study of Ampligen® (rintatolimod) + Imfinzi Combo for the Treatment of Pancreatic Cancer Reported July 29, 2025
Opdivo® IV Infusion Approved in Taiwan in Combination with Yervoy® for Unresectable or Metastatic 1L HCC July 29, 2025
Regulatory Update on Clinical Development Plan for Muzastotug in MSS-CRC Announced Following Productive Type B (End of Ph 1) Meeting with FDA July 23, 2025
First Patient Enrolled in Ph 3 AK112-312/HARMONi-GI6 Trial of Ivonescimab for 1L Metastatic CRC July 23, 2025
CRC Cohort of Ph 2 Trial of PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results July 15, 2025
SIR-Spheres® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable HCC July 15, 2025
Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies announced July 15, 2025
BRAFTOVI® (encorafenib) combo approved in China for treating previously-treated BRAFV600E-mutant metastatic CRC July 15, 2025
Encouraging Survival Data in Patients with Metastatic CRC Previously Treated with Leronlimab Announced July 8, 2025
Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies July 8, 2025
Data from Ongoing Dose Escalation of BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma presented July 8, 2025
BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Ph 3 July 8, 2025
Presentation of positive Ph 1b data for givastomig, nivolumab, and mFOLFOX6 combo in 1L gastric cancer patients announced July 8, 2025
NMPA clears application to evaluate amezalpat (TPST-1120) in combination with atezolizumab and bevacizumab in 1L metastatic HCC patients July 8, 2025
